tiprankstipranks
Top Stocks
Top Analyst StocksTop Smart Score StocksTop Insiders Stocks
Popular
Stock ScreenerTop Online Growth StocksTrending StocksPenny Stock Screener
Dividend Investing
Dividend CalculatorDividend Yield CalculatorDividend StocksDividend NewsDividend Calendar
ETFs
ETF CenterSPY ETFQQQ ETF
Stock Comparison
ChatGPT StocksValue StocksAirline StocksAI StocksOil StocksBank StocksFAANG StocksCompare More Stocks…
Calendars
IPO CalendarEarnings Calendar
Popular
Dividend CalendarEconomic Calendar
New
Market HolidaysDaily Analyst RatingsDaily Insider Trading
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Stock Market NewsStock Analysis & Ideas
Popular
ETF NewsGlobal Markets NewsExpert SpotlightTipRanks LabsEarnings Reports InsightsMarket BreakdownsDividend Stock NewsCrypto News
My PortfolioMy PerformanceMy Portfolio AnalysisCrowd InsightsMy Watchlist
About Us
About TipRanksContact Us
Working with TipRanks
Enterprise SolutionsTools for Trading PlatformsData for Hedge FundsBest Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert Center
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
ETF Center
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Smart Score Stocks
Analysts' Hot Stocks
Insiders' Hot Stocks
Popular
Trending Stocks
Fastest Growing Websites
Hot
Penny Stocks
Market Movers
My Experts
Top Firms
Top Wall Street Analysts
Top Financial Bloggers
Top Corporate Insiders
Popular
Top Hedge Fund Managers
Top Individual Investors
Stock Screener
Stock Comparison
Dividend Calculator
Popular
ETF Center
Dividend Yield Calculator
Daily Stock Ratings
Daily Insider Transactions
Stock ComparisonPOPULAR COMPARISONS
Dividend Stocks
ChatGPT Stocks
Airline Stocks
AI Stocks
My Portfolio
My Performance
My Portfolio Analysis
Crowd Insights
Earnings Calendar
Popular
Dividend Calendar
Economic Calendar
New
IPO Calendar
Stock Market Holidays
Market News
ETF News
Stock Analysis & Ideas
Popular
Global Markets News
Expert Spotlight
Tipranks Labs
Earnings Reports Insights
Market Breakdowns
Dividend Stock News
Crypto News
About TipRanks
For Business
Become an Affiliate
Reviews
Contact Us
Plans & Pricing

VIR Stock Latest News

Vir Biotechnology to Participate in the Barclays Global Healthcare Conference
Press ReleasesVir Biotechnology to Participate in the Barclays Global Healthcare Conference
10d ago
VIR
3 Stocks to Buy Today, 3/6/2023, According to Top Analysts
Stock Analysis & Ideas3 Stocks to Buy Today, 3/6/2023, According to Top Analysts
13d ago
MTH
VIR
Vir Biotechnology price target lowered to $100 from $125 at H.C. Wainwright
The FlyVir Biotechnology price target lowered to $100 from $125 at H.C. Wainwright
13d ago
VIR
Vir Biotechnology upgraded to Overweight from Neutral at JPMorgan
The FlyVir Biotechnology upgraded to Overweight from Neutral at JPMorgan
13d ago
VIR
Vir Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference
Press ReleasesVir Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference
18d ago
VIR
Vir Biotechnology reports Q4 EPS (76c), consensus (39c)
The FlyVir Biotechnology reports Q4 EPS (76c), consensus (39c)
23d ago
VIR
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Press ReleasesVir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
23d ago
VIR
Vir Biotechnology Announces Positive Final Draft Guidance on Sotrovimab from the UK’s National Institute for Health and Care Excellence (NICE)
Press ReleasesVir Biotechnology Announces Positive Final Draft Guidance on Sotrovimab from the UK’s National Institute for Health and Care Excellence (NICE)
25d ago
VIR
Vir Biotechnology announces final draft guidance on sotrovimab from U.K.’s NICE
The FlyVir Biotechnology announces final draft guidance on sotrovimab from U.K.’s NICE
25d ago
VIR
Vir Biotechnology upgraded to Buy from Neutral at Goldman Sachs
The FlyVir Biotechnology upgraded to Buy from Neutral at Goldman Sachs
26d ago
VIR
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
Press ReleasesVir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
1M ago
VIR
Vir Biotechnology appoints Sung Lee as Chief Financial Officer
The FlyVir Biotechnology appoints Sung Lee as Chief Financial Officer
1M ago
MOR
VIR
Vir Biotechnology Announces Amended Collaboration Agreement with GSK
Press ReleasesVir Biotechnology Announces Amended Collaboration Agreement with GSK
1M ago
VIR
Vir Biotechnology announces amended collaboration pact with GSK
The FlyVir Biotechnology announces amended collaboration pact with GSK
1M ago
GSK
VIR
Vir Biotechnology upgraded to Equal Weight from Underweight at Morgan Stanley
The FlyVir Biotechnology upgraded to Equal Weight from Underweight at Morgan Stanley
2M ago
VIR
Vir Biotechnology announces retirement of CEO, Backer to succeed
The FlyVir Biotechnology announces retirement of CEO, Backer to succeed
2M ago
VIR
Vir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successor
Press ReleasesVir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successor
2M ago
VIR
Vir Biotechnology Achieves Target Enrollment for Groundbreaking Phase 2 PENINSULA Trial Evaluating VIR-2482 for Prevention of Seasonal Influenza A
Press ReleasesVir Biotechnology Achieves Target Enrollment for Groundbreaking Phase 2 PENINSULA Trial Evaluating VIR-2482 for Prevention of Seasonal Influenza A
3M ago
VIR
Vir Biotechnology achieves target enrollment for Phase 2 PENINSULA trial
The FlyVir Biotechnology achieves target enrollment for Phase 2 PENINSULA trial
3M ago
VIR
Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500™
Press ReleasesVir Biotechnology Ranked the Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500™
4M ago
VIR
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection
Press ReleasesVir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection
4M ago
VIR
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD’s The Liver Meeting® 2022
Press ReleasesVir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD’s The Liver Meeting® 2022
5M ago
VIR
Vir Biotechnology to Participate in the H. C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference
Press ReleasesVir Biotechnology to Participate in the H. C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference
5M ago
VIR
Vir Biotechnology to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
Press ReleasesVir Biotechnology to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
6M ago
VIR
These Stocks Are the Biggest Pre-Market Movers on Wednesday
Market NewsThese Stocks Are the Biggest Pre-Market Movers on Wednesday
7M ago
TTD
VIR
Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B Program
Press ReleasesVir Biotechnology Announces New Clinical Data From its Broad Hepatitis B Program
9M ago
VIR
FDA Suspends Vir’s Sotrovimab; Shares Drop
Market NewsFDA Suspends Vir’s Sotrovimab; Shares Drop
12M ago
GSK
VIR
Vir Soars 15% on Index Inclusion?
Market NewsVir Soars 15% on Index Inclusion?
12M ago
VIR
These Stocks are the Biggest Pre-Market Movers on Wednesday
Market NewsThese Stocks are the Biggest Pre-Market Movers on Wednesday
12M ago
HXL
VIR
tipranks
TipRanks is a comprehensive research tool that helps investors make better, data-driven investment decisions.
Find Us on
twitterstocktwitsfacebooklinkedininstagram
Newsletter SubscriptionEnter your email to receive our newsletter
iosandroid
SitemapTerms of UsePrivacy PolicyFAQ
Research ToolsTop Smart Score StocksTrending StocksDaily Stock RatingsStock ScreenerStock ComparisonAnalysts' Top StocksDaily Insider TransactionsInsiders' Hot StocksExpert Center
CalendarsEarnings CalendarDividend CalendarIPO CalendarStock Market Holidays
EducationGlossaryTipRanks Labs
PlansPlans & PricingAPI for Institutions
CompanyAbout TipRanksContact UsReviews
Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Changes in these assumptions may have a material impact on the backtested returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions. This information is provided for illustrative purposes only. Backtested performance is developed with the benefit of hindsight and has inherent limitations. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Actual performance may differ significantly from backtested performance. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Please note all regulatory considerations regarding the presentation of fees must be taken into account. No cash balance or cash flow is included in the calculation.